Christopher Sweeney, MBBS
@ChrisSweens1
Followers
4K
Following
1K
Media
73
Statuses
1K
Cancer Researcher & Oncologist Prior @DanaFarber, Prof of Med @Harvardmed. Member @Uromigos. Dec 2022 Director @SAiGENCI and Prof at Uni of Adelaide. Views mine
Joined July 2015
Eurasia 🇨🇳 🇯🇵 🇮🇳 🇪🇺 🇦🇺 now 5-0 up vs the Americas 🇨🇦 🇺🇸 in the Uromigos cup 🏆 - with team Japan 🇯🇵 🇯🇵 winning the last photo competition. Here is team Eurasia’s latest photo. Chris Sweeney from Australias beaches !! 🇦🇺 🏖️ 🇦🇺 🏝️ 🇦🇺 🏖️ 🇦🇺 ❤️ =points @ChrisSweens1 @OncoAlert
0
12
46
@DrChoueiri @DanaFarber @Si @DanaFarber_GU @mishabeltran @DanaFarberNews @COVID19Tracking Giving the @ChrisSweens1 #ProstateCancer lecture was the honor of a lifetime! Deeply grateful to exchange ideas with so many brilliant colleagues @DanaFarber! New collaborations on the way. Many thanks @mishabeltran @DrChoueiri! @PCF_Science @UWCarbone
0
3
17
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial https://t.co/3UXWsmT7FD The 10-year follow-up of the CHAARTED trial confirms that adding docetaxel to
1
25
53
What a great speaker and I am so honoured with the naming of this seminar and the amazing speakers who have lectured in the past and now Josh in 2025! @SAiGENCI @DrChoueiri @mishabeltran @DrKarenKnudsen @AminaZoubeidi
Welcoming @JoshLangMD to @DanaFarber Grand Rounds/Seminars in Oncology next week ! cc: @DanaFarber_GU @DanaFarberNews @mishabeltran @ChrisSweens1 @UWCarbone
3
4
30
Welcoming @JoshLangMD to @DanaFarber Grand Rounds/Seminars in Oncology next week ! cc: @DanaFarber_GU @DanaFarberNews @mishabeltran @ChrisSweens1 @UWCarbone
3
12
57
Incredibly grateful to the mentorship and support from entire @eaonc #GU team @ChrisSweens1 @cityofhope @CityofHope_GU @montypal @DrRaviSalgia @TDorffOnc
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial https://t.co/3UXWsmT7FD The 10-year follow-up of the CHAARTED trial confirms that adding docetaxel to
2
13
40
Excited to share our study Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancer @EmilyGrist1 @marina_parry @MRCCTU @uclcancer @ProstateUK @PCFnews @Prof_Nick_James @LotanLab @Decipher_VCYT @ChrisSweens1
2
29
63
Prostate tumours classified as high Decipher and PTEN inactive have a 45% reduction in hazard of death when Doce is added to ADT. This biomarker should be tested in pts considered for triplet therapy.
1
6
14
Tests using the same technology are currently in routine use in localised prostate cancer and breast cancer, so the assay can be efficiently and rapidly transitioned into clinical practice.
1
1
5
We are incredibly grateful to funders @ProstateUK @PCFnews @PCR_News (among others), collaborators @MRCCTU @Decipher_VCYT, STAMPEDE @Prof_Nick_James @GUresearch_MCR and CHAARTED @ChrisSweens1 trial teams, and to all the STAMPEDE patients who donated their tissue to our study.
1
1
9
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol https://t.co/F5U64bm1SC In the STAMPEDE phase 3 trial, researchers evaluated whether adding metformin to standard of care
1
32
84
Online: Metformin for patients with metastatic #prostatecancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol @Silke_Gillessen, @Prof_Nick_James, @AshwinUrol, and colleagues https://t.co/esZJWCiFaj
3
13
32
And 33% still on upfront enzalutamide at 8 years with no disease progression
#ENZAMET @ANZUPtrials @TrialsCentre #ASCO25 ✅ 50% survival at 8yr vs 40% - sustained, all subgroups ✅ non-#ProstateCancer deaths same in both arms: removes doubts of long term safety and benefit re competing causes of death ✅ undetectable PSA is good; more likely with enza
1
9
39
#ENZAMET @ANZUPtrials @TrialsCentre #ASCO25 ✅ 50% survival at 8yr vs 40% - sustained, all subgroups ✅ non-#ProstateCancer deaths same in both arms: removes doubts of long term safety and benefit re competing causes of death ✅ undetectable PSA is good; more likely with enza
8-year outcomes of enzalutamide vs a non-steroidal anti-androgen for metastatic, hormone-sensitive #ProstateCancer (ENZAMET; ANZUP 1304). Presented by Alison Zhang, MD, PhD @Sydney_Uni. #ASCO25 written coverage by @RKSayyid @USC > https://t.co/5UUNf83t4i
@ASCO
0
15
36
#BCGMM presented by Dickon Hayne at #ASCO25. Simple question, hard trial, needed a cooperative group like @ANZUPtrials @TrialsCentre. Discussant @DrJohnSfakianos v enthusiastic, one of the most impactful #NMIBC trials he has seen, will change his practice. #BladderCancer #blcsm
0
7
8
Great to see @ANZUPTrials #ENZAMET 8-year outcomes poster at #ASCO25 presented by Alison Zhang @ChrisSweens1 @Prof_IanD @TrialsCentre @cancertrials_ie @CDNCancerTrials @AstellasUS #CancerAustralia
#ENZAMET @ANZUPtrials @TrialsCentre #ASCO25 ✅ 50% survival at 8yr vs 40% - sustained, all subgroups ✅ non-#ProstateCancer deaths same in both arms: removes doubts of long term safety and benefit re competing causes of death ✅ undetectable PSA is good; more likely with enza
1
6
17
🚨 New episode alert! @Silke_Gillessen and @ChrisSweens1 join us to discuss our latest 'Uromigos Score' in which experts score the value of treatments for advanced prostate cancer. Expect some interesting themes and insights. 🎙️ GU Oncology Now: https://t.co/ZlJRGfFpyF 🍎
0
12
35
Great to see a full-house for @SAiGENCI's third Annual Public Lecture on Tuesday night featuring @Lab_Jenkins and @marazeissig speaking on the topic of "Fighting cancer from within: your immune system may hold the key" https://t.co/cyM2wx9iOT
@UniofAdelaide
0
4
10